鼻咽癌靶向治疗及免疫治疗的研究进展  

Progress of Targeted Therapy and Immunotherapy for Nasopharyngeal Carcinoma

作　　者：陈涵波 狄文忆 张煜婕 古亮 陈杰[1,3] 何侠 尹丽[1,2] CHEN Han-bo;DI Wen-yi;ZHANG Yu-jie;GU Liang;CHEN Jie;HE Xia;YIN Li(The Affiliated Cancer Hospital of Nanjing Medical University&Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research,Nanjing 210009,China;The Fourth School of Clinical Medicine,Nanjing Medical University,Nanjing 210000,China;Xuzhou Medical University,Xuzhou 221000,China)

机构地区：[1]南京医科大学附属肿瘤医院&江苏省肿瘤医院&江苏省肿瘤防治研究所,江苏南京210009 [2]南京医科大学第四临床医学院,江苏南京210000 [3]徐州医科大学,江苏徐州221000

出　　处：《肿瘤学杂志》2020年第4期275-282,共8页Journal of Chinese Oncology

基　　金：国家自然科学基金(81702685;81672989);江苏省卫生厅青年医学人才基金(QNRC2016648);中国博士后科学基金(2018M632266);博士后科研经费(SZL201705)。

摘　　要：鼻咽癌治疗方式主要包括放疗和化疗。近几年,尽管治疗方案有较多进展,但是局部复发或远处转移常常导致治疗失败。鼻咽癌与爱泼斯坦-巴尔病毒(EBV)感染、肿瘤淋巴细胞浸润(TIL)和程序性死亡受体1(PD-1)或其配体(PD-L1)表达增加有关,这些都可能成为治疗靶点,因此靶向及免疫治疗可能是未来的发展方向。目前有多项临床研究正在进行,验证了靶向及免疫治疗在鼻咽癌治疗中具有潜力,特别是在治疗复发或转移性鼻咽癌方面取得了突破进展。全文就靶向及免疫治疗在鼻咽癌中的研究进行综述。Radiotherapy and chemotherapy are the main therapeutic modalities for nasopharyngeal carcinoma. In recent years,despite advances in treatment regimens,local recurrence or distant metastasis often leads to treatment failure. Nasopharyngeal carcinoma is associated with Epstein-Barr virus(EBV),tumor infiltration lymphocyte(TIL),and increased expression of PD-1 or its ligand PD-L1,which are potential therapeutic targets. Therefore,targeted therapy and immunotherapy may be the direction of future development. At present,a number of clinical studies are under way to verify the efficacy of targeted therapy and immunotherapy in the treatment of nasopharyn-geal carcinoma,especially in the treatment of recurrent or metastatic nasopharyngeal carcinoma.This review focuses on the recent research progress of targeted therapy and immunotherapy in na-sopharyngeal carcinoma.

关 键 词：鼻咽肿瘤 EBV 靶向治疗 免疫治疗 

分 类 号：R739.63[医药卫生—肿瘤]